The present disclosure provides compositions, methods and kits for internal controls of microvesicle isolations. The compositions, methods and kits can comprise enveloped viruses, including, but not limited to, inactive mouse hepatitis virus (MHV).

Provided herein are fragment length profiles of nucleic acid libraries, methods of generating fragment length profiles of nucleic acid libraries and methods of using fragment length profiles for diagnostics and/or prognostics. The application further provides methods, compositions and kits for determining the infection stage or the site of localization in a subject.

Provided herein are fragment length profiles of nucleic acid libraries, methods of generating fragment length profiles of nucleic acid libraries and methods of using fragment length profiles for diagnostics and/or prognostics. The application further provides methods, compositions and kits for determining the infection stage or the site of localization in a subject.

The present disclosure relates in some aspects to methods for analyzing a target nucleic acid in a biological sample. In some aspects, the methods involve the use of a set of polynucleotides, including one or more polynucleotides (e.g., a detection padlock probe) for detecting a region of interest and one or more polynucleotides (e.g., a control padlock probe) as an internal control, for analyzing target nucleic acids. In some aspects, the presence, amount, and/or identity of a region of interest in a target nucleic acid is analyzed in situ. Also provided are polynucleotides, sets of polynucleotides, compositions, and kits for use in accordance with the methods.

The present disclosure relates in some aspects to methods for analyzing a target nucleic acid in a biological sample. In some aspects, the methods involve the use of a set of polynucleotides, including one or more polynucleotides (e.g., a detection padlock probe) for detecting a region of interest and one or more polynucleotides (e.g., a control padlock probe) as an internal control, for analyzing target nucleic acids. In some aspects, the presence, amount, and/or identity of a region of interest in a target nucleic acid is analyzed in situ. Also provided are polynucleotides, sets of polynucleotides, compositions, and kits for use in accordance with the methods.

The invention provides a method for validating patient-specific oligos using spike-in sequences.

The invention provides a method for validating patient-specific oligos using spike-in sequences.

The present invention provides synthetic DNA strands that find use as process controls in DNA processing and nucleic acid testing methods. In particular, provided herein are synthetic methylated DNA strands of known composition for use as control molecules in DNA testing, e.g., of mutations and/or methylation of DNA isolated from non-fish samples, such as human samples.

The present invention provides synthetic DNA strands that find use as process controls in DNA processing and nucleic acid testing methods. In particular, provided herein are synthetic methylated DNA strands of known composition for use as control molecules in DNA testing, e.g., of mutations and/or methylation of DNA isolated from non-fish samples, such as human samples.

Provided are a method for predicting the effect of Daikenchuto, a method for determining the dosage of Daikenchuto, etc. using an objective index by a method for predicting the effectiveness of Daikenchuto in a patient characterized by including the following steps (a) and (b): (a) a step of determining the ratio of the phylum Bacteroidetes to the phylum Firmicutes (B.sub.m/F.sub.m ratio) in the intestine of the patient by analyzing the intestinal flora of the patient; and (b) a step of determining the effectiveness of Daikenchuto in the patient by comparison with criteria such that when the B.sub.m/F.sub.m ratio is lower than a reference value, Daikenchuto is more effective, and when the B.sub.m/F.sub.m ratio is higher than a reference value, Daikenchuto is less effective, and a method for determining the dosage of Daikenchuto for a patient characterized by including the following steps (a) and (e): (a) a step of determining the ratio of the phylum Bacteroidetes to the phylum Firmicutes (B.sub.m/F.sub.m ratio) in the intestine of the patient by analyzing the intestinal flora of the patient, and (e) a step of determining the dosage of Daikenchuto for the patient by decreasing the dosage of Daikenchuto for the patient when the B.sub.m/F.sub.m ratio determined in the step (a) is a lower value than a reference value, and increasing the dosage of Daikenchuto for the patient when the B.sub.m/F.sub.m ratio is a higher value than a reference value.